Disclosure: Has served as a consultant on an advisory board for UCB

Disclosure: None

Disclosure: CorEvitas, LLC employee

Disclosure: CorEvitas, LLC employee

Disclosure: CorEvitasa, LLC employee

Disclosure: CorEvitas, LLC employee

Disclosure: (Grant/Research Support) Celgene, Lilly, AbbVie; Consultant: Amgen, Boehringer Ingelheim, BMS, UCB.

Acknowledgements: The authors thank the participating providers and patients for contributing data to CorEvitas’ Psoriasis Registry. This study was supported through a partnership between Psoriasis Registry and the National Psoriasis Foundation Medical Board.

Funding sources: This study was sponsored by CorEvitas (formerly Corrona), LLC and the analysis was funded by CorEvitas LLC. Access to study data was limited to CorEvitas and CorEvitas statisticians completed all of the analysis; all authors contributed to the interpretation of the results. CorEvitas has been supported through contracted subscriptions in the last two years by AbbVie, Amgen, Arena, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Chugai, Eli Lilly and Company, Genentech, Gilead, GSK, Janssen, LEO, Novartis, Ortho Dermatologics, Pfizer Inc., Regeneron, Sanofi, Sun and UCB. IRB approval status: Exempt